Please try another search
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Name | Age | Since | Title |
---|---|---|---|
Peter Salzmann | 55 | 2019 | CEO & Director |
Andrew J. Fromkin | 56 | 2019 | Director |
Atul C. Pande | 68 | 2019 | Independent Director |
Eric Venker | 36 | 2020 | Director |
Frank M. Torti | 44 | 2019 | Executive Chairperson of the Board |
George V. Migausky | 69 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review